FDA approval expands range of Metadate (methylphenidate) dosages
The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Medadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).
The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Metadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).
The capsules are already available in 10 mg, 20 mg, and 30 mg strengths, with a recommended starting dose of 20 mg once daily.
"The new strengths will allow for the full range of immediate-release doses (30% of the total) from a single capsule," said James M. Swanson, MD, PhD, professor of pediatrics at the University of California, Irvine. "The addition of these doses will allow physicians greater flexibility in tailoring a treatment regimen to the individual needs and responses of each patient."
Michael Daines, MD, discusses pediatric acute-onset neuropsychiatric syndrome
June 12th 2025Michael O. Daines, MD, outlines key diagnostic criteria and treatment challenges for pediatric acute-onset neuropsychiatric syndrome (PANS), emphasizing the need for multidisciplinary care and improved treatment access.
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
June 12th 2025Aaron Milstone, MD, MHS, emphasizes the role of pediatricians in educating families on infection prevention practices for infants in the NICU, where Staphylococcus aureus remains a serious threat.
